Answer
Olmesartan medoxomil/hydrochlorothiazide is not recommended during breastfeeding because safety information is unavailable and hydrochlorothiazide enters milk and, at high doses causing intense diuresis, can suppress milk production; alternatives with better-established safety are preferred, especially for newborn or preterm infants, and doses should be as low as possible if used.
Sources for this answer
- Olmesartan medoxomil/Hydrochlorothiazide 20 mg/12.5 mg and 20 mg/25 mg film-coated tabletsMSN Laboratories Europe Ltd · emc · SmPC §4.6 Fertility, pregnancy and lactation · Version 1Document updated
Sources checked